JP7518547B2 - 統合失調症及び他の神経精神障害の治療方法 - Google Patents

統合失調症及び他の神経精神障害の治療方法 Download PDF

Info

Publication number
JP7518547B2
JP7518547B2 JP2021533154A JP2021533154A JP7518547B2 JP 7518547 B2 JP7518547 B2 JP 7518547B2 JP 2021533154 A JP2021533154 A JP 2021533154A JP 2021533154 A JP2021533154 A JP 2021533154A JP 7518547 B2 JP7518547 B2 JP 7518547B2
Authority
JP
Japan
Prior art keywords
smad4
composition
glial
subject
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021533154A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022511568A (ja
JP2022511568A5 (OSRAM
Inventor
スティーブン エー． ゴールドマン
チェンシャン リュー
Original Assignee
ユニバーシティー オブ ロチェスター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティー オブ ロチェスター filed Critical ユニバーシティー オブ ロチェスター
Publication of JP2022511568A publication Critical patent/JP2022511568A/ja
Publication of JP2022511568A5 publication Critical patent/JP2022511568A5/ja
Priority to JP2024104638A priority Critical patent/JP2024129091A/ja
Application granted granted Critical
Publication of JP7518547B2 publication Critical patent/JP7518547B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/122—Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
JP2021533154A 2018-12-11 2019-12-11 統合失調症及び他の神経精神障害の治療方法 Active JP7518547B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024104638A JP2024129091A (ja) 2018-12-11 2024-06-28 統合失調症及び他の神経精神障害の治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862778145P 2018-12-11 2018-12-11
US62/778,145 2018-12-11
PCT/US2019/065742 WO2020123663A1 (en) 2018-12-11 2019-12-11 Methods of treating schizophrenia and other neuropsychiatric disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024104638A Division JP2024129091A (ja) 2018-12-11 2024-06-28 統合失調症及び他の神経精神障害の治療方法

Publications (3)

Publication Number Publication Date
JP2022511568A JP2022511568A (ja) 2022-01-31
JP2022511568A5 JP2022511568A5 (OSRAM) 2022-12-15
JP7518547B2 true JP7518547B2 (ja) 2024-07-18

Family

ID=69160318

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021533154A Active JP7518547B2 (ja) 2018-12-11 2019-12-11 統合失調症及び他の神経精神障害の治療方法
JP2024104638A Pending JP2024129091A (ja) 2018-12-11 2024-06-28 統合失調症及び他の神経精神障害の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024104638A Pending JP2024129091A (ja) 2018-12-11 2024-06-28 統合失調症及び他の神経精神障害の治療方法

Country Status (7)

Country Link
US (1) US20220025379A1 (OSRAM)
EP (1) EP3894556A1 (OSRAM)
JP (2) JP7518547B2 (OSRAM)
CN (2) CN119925614A (OSRAM)
AU (1) AU2019396450B2 (OSRAM)
CA (1) CA3122289A1 (OSRAM)
WO (1) WO2020123663A1 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9709553B2 (en) 2008-05-08 2017-07-18 University Of Rochester Treating myelin diseases with optimized cell preparations
WO2014124087A1 (en) 2013-02-06 2014-08-14 University Of Rochester Induced pluripotent cell-derived oligodendrocyte progenitor cells for the treatment of myelin disorders
US9724432B2 (en) 2015-04-30 2017-08-08 University Of Rochester Non-human mammal model of human degenerative disorder, uses thereof, and method of treating human degenerative disorder
JP7457505B2 (ja) 2017-05-10 2024-03-28 ユニバーシティー オブ ロチェスター 神経精神障害を処置する方法
KR20210054502A (ko) 2018-06-21 2021-05-13 유니버시티 오브 로체스터 헌팅턴병을 치료하거나 이의 발병을 저해하는 방법
CN118924886A (zh) * 2023-03-16 2024-11-12 郑州大学 肿瘤共享新抗原表位肽或其编码核酸的新用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080119427A1 (en) 1996-06-06 2008-05-22 Isis Pharmaceuticals, Inc. Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US6838283B2 (en) 1998-09-29 2005-01-04 Isis Pharmaceuticals Inc. Antisense modulation of survivin expression
PT1152009E (pt) 1999-02-12 2005-03-31 Sankyo Co Novos analogos de nucleosidos e oligonucleotidos
US6013787A (en) 1999-02-23 2000-01-11 Isis Pharmaceuticals Inc. Antisense modulation of Smad4 expression
US7098192B2 (en) 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
US7179796B2 (en) 2000-01-18 2007-02-20 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
WO2003070918A2 (en) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
JP2005504020A (ja) 2001-07-03 2005-02-10 アイシス・ファーマシューティカルス・インコーポレーテッド ヌクレアーゼ耐性キメラオリゴヌクレオチド
ES2280826T5 (es) 2002-08-05 2017-08-03 Silence Therapeutics Gmbh Nuevas formas adicionales de moléculas de ARN de interferencia
SG146682A1 (en) 2003-09-18 2008-10-30 Isis Pharmaceuticals Inc Modulation of eif4e expression
US7128264B2 (en) 2004-07-23 2006-10-31 Symbol Technologies, Inc: Electro-optical reader with improved performance in high intensity ambient light
JP4428296B2 (ja) 2005-06-10 2010-03-10 セイコーエプソン株式会社 表示パネルモジュールおよび表示装置
US9962558B2 (en) * 2005-08-05 2018-05-08 Gholam A. Peyman Methods to regulate polarization and enhance function of cells
CN101864392B (zh) 2005-12-13 2016-03-23 国立大学法人京都大学 核重新编程因子
EP3399025B1 (en) 2007-03-23 2025-05-07 Wisconsin Alumni Research Foundation Somatic cell reprogramming
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
WO2010017562A2 (en) 2008-08-08 2010-02-11 Mayo Foundation For Medical Education And Research Induced pluripotent stem cells
US20120276070A1 (en) 2009-11-17 2012-11-01 Vitro Diagnositics, Inc. Induced Pluripotent Stem Cells and Related Methods
EP2526189B1 (en) 2010-01-22 2016-10-12 Kyoto University Method for improving induced pluripotent stem cell generation efficiency
US9228188B2 (en) * 2011-06-21 2016-01-05 Alnylam Pharmaceuticals, Inc. Compositions and method for inhibiting hepcidin antimicrobial peptide (HAMP) or HAMP-related gene expression
CN113528442A (zh) * 2011-11-04 2021-10-22 纪念斯隆-凯特琳癌症中心 用于植入的中脑多巴胺（da）神经元
US9035039B2 (en) 2011-12-22 2015-05-19 Protiva Biotherapeutics, Inc. Compositions and methods for silencing SMAD4
WO2016115558A2 (en) 2015-01-16 2016-07-21 Bruno Doiron Compositions and methods for creating pancreatic cancer animal model

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Front. Pharmacol.，2018年，9，Article.845(p.1-9)，<DOI:10.3389/fphar.2018.00845>
Int. Clin. Psychopharmacol.，2014年，29, [4]，p.235-238
Jpn. J. Gen. Hosp. Psychiatry，2011年，23, [1]，p.27-34
Medicine，2016年，95, [4]，Article.e2475(p.1-10)，<DOI:10.1097/MD.0000000000002475>
Neuroscience，2018年，388，p.102-117

Also Published As

Publication number Publication date
CN113728103B (zh) 2025-02-28
JP2022511568A (ja) 2022-01-31
CN119925614A (zh) 2025-05-06
WO2020123663A1 (en) 2020-06-18
EP3894556A1 (en) 2021-10-20
CA3122289A1 (en) 2020-06-18
US20220025379A1 (en) 2022-01-27
JP2024129091A (ja) 2024-09-26
AU2019396450A1 (en) 2021-06-24
AU2019396450B2 (en) 2025-08-28
CN113728103A (zh) 2021-11-30

Similar Documents

Publication Publication Date Title
JP7555542B2 (ja) 統合失調症及び他の神経精神障害の治療方法
JP2024129091A (ja) 統合失調症及び他の神経精神障害の治療方法
CN114514038B (zh) 胶束纳米颗粒及其用途
JP2024023379A (ja) ハンチントン病を治療するまたはその発症を阻害する方法
CN103189511B (zh) 利用siRNA导入的新型hiPSC制作法
KR20190051020A (ko) 안 질환 치료용 안티센스 올리고뉴클레오타이드
CN113811311A (zh) 用于组织特异性apoe调节的寡核苷酸
JP2018138044A (ja) 神経栄養因子を分泌する間葉系幹細胞の作製方法
JP2021520200A (ja) 非神経細胞のニューロンへの再プログラミング、及び神経変性疾患または障害を治療するための方法と組成物
IL301610A (en) Compositions and methods for modulating TCF4 gene expression and treating Pitt Hopkins syndrome
US20190015453A1 (en) MicroRNAS FOR THE GENERATION OF ASTROCYTES
EP4249589A1 (en) In vitro genetic disease model cell and method for producing the same
EP4599062A1 (en) Unc13a antisense oligonucleotides and uses thereof
US20260022377A1 (en) Polynucleotide compositions and methods for treatment of neurodegenerative diseases
JPWO2013162027A1 (ja) 神経分化促進剤
KR20250057176A (ko) Arid4b 유전자 발현을 통한 신경세포로의 직접교차분화 유도 방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221207

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230824

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240228

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240530

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240628

R150 Certificate of patent or registration of utility model

Ref document number: 7518547

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150